Drug
Zd1839
Zd1839: highest development phase Phase 2, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| ZD1839 NCT00048087 | Phase 2 | Non-small Cell Lung Cancer |
Latest
No recent events.
Follow Zd1839 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.